Dimerix Limited · ASX:DXB
Dimerix — Shareholder Meeting (November 2022)
18 slides from Dimerix's shareholder meeting presentation, Nov 29, 2022
Slide 1: Chairman's Address – 2022 Dimerix Annual General Meeting
For Immediate Release CHAIRMAN’S ADDRESS – 2022 DIMERIX ANNUAL GENERAL MEETING 29 November 2022 Ladies and gentlemen, The 2021-22 Financial Year was perhaps the most pivotal in our company’s history as we completed the planning phase for our Phase 3 trial into Focal Segmental Glomerulosclerosis (FSG
Slide 2: Chairman's address continued: partnering and shareholder thanks
Of course each clinical study is different, but these statistics reflect the reality that in order to progress to Phase 3, a drug candidate must have demonstrated both safety and some aspects of efficacy, and so the odds of success go from 1 : 7.2 for Phase 1, to better than even (1 : 1.7) in Phase
Slide 3: About Dimerix / References
About Dimerix Dimerix (ASX: DXB) is a clinical-stage biopharmaceutical company developing innovative new therapies in areas with unmet medical needs for global markets. Dimerix is currently developing its proprietary product DMX-200, for Focal Segmental Glomerulosclerosis (FSGS), respiratory complic
Slide 4: Company Review
Company Review Dr Nina Webster CEO & Managing Director @ Dimerix
Slide 5: Forward looking statements
Forward looking statements This presentation includes forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks and important factors that may cause the actual results, performance or achievements of Dimerix to be materially different-fro
Slide 6: Key company metrics
Key company metrics Phase 3 trial FUNDED Strong outlook with potential for significant value upside? @ Dimerix
Slide 7: Key achievements — FY22
Key achievements — FY22 $6 million R&D FSGS Part 190% rebate received recruited lovembel 2022 Expanded IP. DMX-700 COPD portfolio Positive pre- Diabetic kidney 3 clinical data disease collaboration eee” with ACADI fa CLARITY 2.0 os closed recruitment closed recruitment.” Patients Dosed in DMX-200 CO
Slide 8: Development pipeline
Development pipeline Program Indication Preclinical Phase 1 Phase 2 DMX-200 00 -------------- = 2-22-22 ee en nn enn en ne nnn nnn nn nn nnn nn nen nee ee eee Late COVID pneumonia — Investigator-led REMAP-CAP Recruitment closed - pending data Early COVID respiratory — Investigator-led CLARITY 2.0 Re
Slide 9: ACTION3 FSGS Clinical Study Phase 3 Update
ACTION3 FSGS CLINICAL STUDY Phase 3 Update @ Dimerix
Slide 10: Focal Segmental Glomerulosclerosis — rare kidney disease
Focal Segmental Glomerulosclerosis — rare kidney disease Glomeruli are the tiny network of blood vessels that are the “cleaning units” of the kidney Segmental sclerosis =e” 220,000 Total incident population of FSGS across 7 major market: in 202? 20% of child nephrotic syndrome cases caused by FSGS?
Slide 11: ACTION3 - FSGS phase 3 study design
@' ACTI 6) 3 - FSGS phase 3 study design FSGS CLINICAL STUDY A randomised, double-blind, multi-centre, placebo-controlled study of renal outcomes of DMX-200 in patients with FSGS receiving an ARB ARB stabilisation Treatment period weeks -6 1 0 35 104 ' ! c i = ca 2 DMX-200 @ rt = & 21] —€ 5 Ff io] ®
Slide 12: ACTION3 Study part status
@' ACTI e) 3 Study part 1 status FSGS CLINICAL STUDY Patients recruited*: 100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% Estimated Sep Oct ¢ Recruiting globally * On track to complete Part 1 recruitment Q4 2022 * Part 1 completion anticipated Q3-2023** “Actual and estimated as at27Nov2022 Patients recr
Slide 13: Dimerix partnering objectives
Dimerix partnering objectives | Global interest in DMX-200 Dimerix intends to partner DMX-200 No plans for a sales and Actively engaged with potential marketing team, but partner to licensing partners, with the aim support sales and marketing he at ox) to provide the best outcome for activities both
Slide 14: What does commercialisation look like?
What does commercialisation look like? Big Pharma or Mid-Tier or Specialty Pharma Regional Country e.g. North America/EU e.g. Japan only Global Transactions typically comprises: * Acash payment upon execution of a definitive agreement ¢« Acash payment on future key inflection events e.g. data outcom
Slide 15: Renal licensing deals detail
Renal licensing deals detail (only deals where financials disclosed included) Sep 2022 Jul 2022 Jun 2022 Sep 2021 Sep 2021 Sep 2021 Jul 2021 Ventus NovoNordisk $700.0M Roche Pharma ticals Undisclosed Alchemedicine, Inc. Asahi Kasei Pharma $250M Travere Therapeutics Vifor Pharma $845.0M AM-Pharma Hol
Slide 16: Advancing the broader pipeline
Advancing the broader pipeline | sources of revenue Additional longer term pipeline opportunities diversify risk and po DMX-700 for Chronic DMX-200 for Diabetic Obstructive Pulmonary Kidney Disease Disease (COPD) Preclinical studies show that DMX-700 Phase 2 demonstrated promising efficacy & signifi
Slide 17: Investment highlights
Investment highlights Positive Phase FSGS Study Progress Multiple Pi @ Dimerix 14
Slide 18: Dimerix
Dimerix A biopharmaceutical company developing innovative new therapies in areas with unmet medical needs, with a core focus on inflammatory disease treatments such as kidney and respiratory diseases. Well positioned to deliver against strategic plan Dimerix HQ 425 Smith St, Fitzroy 3065 Victoria, A